Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Children's Hospital of Philadelphia (M.J.S., C.M.J., V.R.I.).
Department of Pediatrics, University of California, Rady Children's Hospital, San Diego (A.A.B., M.R.W.).
Circ Arrhythm Electrophysiol. 2023 Apr;16(4):e011447. doi: 10.1161/CIRCEP.122.011447. Epub 2023 Apr 11.
Transcatheter Leadless Pacemakers (TLP) are a safe and effective option for adults with pacing indications. These devices may be an alternative in pediatric patients and patients with congenital heart disease for whom repeated sternotomies, thoracotomies, or transvenous systems are unfavorable. However, exemption of children from clinical trials has created uncertainty over the indications, efficacy, and safety of TLP in the pediatric population. The objectives of this study are to evaluate clinical indications, procedural characteristics, electrical performance, and outcomes of TLP implantation in children.
Retrospective data were collected from patients enrolled in the Pediatric and Congenital Electrophysiology Society TLP registry involving 15 centers. Patients ≤21 years of age who underwent Micra (Medtronic Inc, Minneapolis, MN) TLP implantation and had follow-up of ≥1 week were included in the study.
The device was successfully implanted in 62 of 63 registry patients (98%) at a mean age of 15±4.1 years and included 20 (32%) patients with congenital heart disease. The mean body weight at TLP implantation was 55±19 kg and included 8 patients ≤8 years of age and ≤30 kg in weight. TLP was implanted by femoral (n=55, 87%) and internal jugular (n=8, 12.6%) venous approaches. During a mean follow-up period of 9.5±5.3 months, there were 10 (16%) complications including one cardiac perforation/pericardial effusion, one nonocclusive femoral venous thrombus, and one retrieval and replacement of TLP due to high thresholds. There were no deaths, TLP infections, or device embolizations. Electrical parameters, including capture thresholds, R wave sensing, and pacing impedances, remained stable.
Initial results from the Pediatric and Congenital Electrophysiology Society TLP registry demonstrated a high level of successful Micra device implants via femoral and internal venous jugular approaches with stable electrical parameters and infrequent major complications. Long-term prospective data are needed to confirm the reproducibility of these initial findings.
经导管无导线起搏器(TLP)是起搏适应证成人的安全有效选择。对于需要反复开胸、开胸或经静脉系统的患者,这些设备可能是儿科患者和先天性心脏病患者的替代选择。然而,由于儿童被排除在临床试验之外,因此对于 TLP 在儿科人群中的适应证、疗效和安全性存在不确定性。本研究的目的是评估 TLP 在儿童中的临床适应证、程序特征、电性能和结果。
从参与涉及 15 个中心的儿科和先天性电生理学会 TLP 注册研究的患者中收集回顾性数据。纳入在 1 周以上随访期间接受 Micra(美敦力公司,明尼苏达州明尼阿波利斯)TLP 植入且年龄≤21 岁的患者。
在平均年龄为 15±4.1 岁的 63 名登记患者中,有 62 名(98%)成功植入设备,其中 20 名(32%)患者患有先天性心脏病。TLP 植入时的平均体重为 55±19kg,包括 8 名年龄≤8 岁且体重≤30kg 的患者。TLP 通过股静脉(n=55,87%)和颈内静脉(n=8,12.6%)途径植入。在平均 9.5±5.3 个月的随访期间,有 10 名(16%)患者发生并发症,包括 1 例心脏穿孔/心包积液、1 例非闭塞性股静脉血栓形成和 1 例因高阈值而取出并更换 TLP。无死亡、TLP 感染或设备栓塞。电参数,包括捕获阈值、R 波感知和起搏阻抗,保持稳定。
儿科和先天性电生理学会 TLP 注册研究的初步结果表明,通过股静脉和颈内静脉途径植入 Micra 设备的成功率较高,电参数稳定,严重并发症发生率较低。需要长期前瞻性数据来证实这些初步发现的可重复性。